Tetrapeptide · Fact sheet
Epitalon
Also known as Epithalon · AEDG
Epitalon has changed telomerase activity and telomere length in cell experiments. Those findings do not show that it extends human life, reverses aging, or improves sleep, and it is not FDA approved.
What is Epitalon?
Epitalon is a synthetic four-amino-acid peptide. It should not be treated as interchangeable with epithalamin, a tissue-derived preparation used in some older reports.
Telomeres are chromosome-end structures; changing them in cultured cells is different from improving health in a person.
Benefits & claims
Longevity, sleep regularity, and a younger biological age are the main claims readers encounter. Cell-lifespan findings cannot answer those questions on their own.
What the evidence supports
- A 2003 experiment reported telomerase activation and telomere extension in cultured fibroblasts.
- More recent cell work explored different mechanisms in normal and cancer cell lines; it does not demonstrate a human longevity benefit.
Research areas
- Telomerase activity
- Telomere biology
- Cellular aging
Dosage & frequency
No established human regimenEpitalon research does not establish a human longevity treatment dose or repeat-cycle schedule. Cell telomerase findings are not a dosing guide.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Epitalon is a defined short peptide; heterogeneous epithalamin preparations are different evidence.
Interactions & precautions
- A validated human drug-interaction profile is not established; cell telomerase experiments do not answer combination safety.
What is still unresolved
- A validated human formulation, regimen, clinical benefit, and long-term safety profile remain unresolved.
Side effects & risks
- FDA flags immune-response and impurity concerns and missing route-specific safety information.
- Cell experiments cannot establish long-term cancer safety or quantify adverse effects in people.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe cited telomere experiments used cultured human cells, not clinical treatment of people. A 2025 cell-line paper also has a published correction linked in the source record.
Studies
Cell experiment, not a human longevity trial.
Normal and cancer cell experiments; see the linked published correction.
Correction replacing incorrectly published figures 1–3; the original article has been corrected.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Sleepless nights and daytime exhaustion
An author with pre-existing fragmented sleep described two sleepless nights and feeling exhausted after trying Epitalon.
Reported use in this account
- Product
- Product described as Epitalon
- Amount
- 500 mcg on each reported night
- Frequency
- On two consecutive nights
- Route
- Not specified clearly
- Duration
- Two nights
The short account cannot separate the compound from ongoing insomnia or verify its contents.
Read the original accountMore daytime energy, but early waking
Another author described falling asleep, then waking after a few hours and being unable to return to sleep, despite feeling energetic and in a good mood during the day.
Reported use in this account
- Product
- Product described as Epitalon
- Amount
- 1 mg, 5 mg and 10 mg were reported at different times
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Ten days at 10 mg; approximately a week at 1 mg were described
This subjective pattern does not establish improved sleep quality, a circadian mechanism or a long-term benefit.
Read the original accountSleep: reported experiences
Sleepless nights and daytime exhaustion
An author with pre-existing fragmented sleep described two sleepless nights and feeling exhausted after trying Epitalon.
Reported use in this account
- Product
- Product described as Epitalon
- Amount
- 500 mcg on each reported night
- Frequency
- On two consecutive nights
- Route
- Not specified clearly
- Duration
- Two nights
The short account cannot separate the compound from ongoing insomnia or verify its contents.
Read the original accountMore daytime energy, but early waking
Another author described falling asleep, then waking after a few hours and being unable to return to sleep, despite feeling energetic and in a good mood during the day.
Reported use in this account
- Product
- Product described as Epitalon
- Amount
- 1 mg, 5 mg and 10 mg were reported at different times
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Ten days at 10 mg; approximately a week at 1 mg were described
This subjective pattern does not establish improved sleep quality, a circadian mechanism or a long-term benefit.
Read the original accountBetter sleep reported during several simultaneous exposures
A commenter in a DSIP discussion reported less interrupted sleep while also using a product labeled Epithalon and multiple other supplements.
Amount, frequency, route and duration could not be confirmed for this account.
Nothing in this account isolates Epitalon. It provides no evidence of telomere effects, life extension or a stand-alone sleep benefit.
Read the combined-exposure accountMood: reported experiences
More daytime energy, but early waking
Another author described falling asleep, then waking after a few hours and being unable to return to sleep, despite feeling energetic and in a good mood during the day.
Reported use in this account
- Product
- Product described as Epitalon
- Amount
- 1 mg, 5 mg and 10 mg were reported at different times
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Ten days at 10 mg; approximately a week at 1 mg were described
This subjective pattern does not establish improved sleep quality, a circadian mechanism or a long-term benefit.
Read the original accountApproval status
Epitalon has no FDA-approved product. Laboratory telomere studies and older reports on related preparations do not document an approved anti-aging treatment.
No established FDA drug approval path
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Effects on human lifespan or age-related disease
- Reliable sleep outcomes
- Long-term effects on cell growth and cancer risk
Summary
Epitalon is an experimental aging research topic, with a large gap between cell findings and demonstrated human outcomes.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- pubmedEpitalon and telomere length in cell lines
Normal and cancer cell experiments; see the linked published correction.
- pubmedCorrection to the 2025 epitalon cell study
Correction replacing incorrectly published figures 1–3; the original article has been corrected.